Metabolic/JJ
Syndrome/NN
Prediction/NN
Using/VBG
Machine/NN
Learning/JJ
Models/NNS
with/IN
Genetic/JJ
and/CC
Clinical/JJ
Information/NN
from/IN
a/DT
Nonobese/JJ
Healthy/NN
Population/NN
./.
====================
The/DT
prevalence/NN
of/IN
metabolic/JJ
syndrome/NN
(/(
MS/NN
)/)
in/IN
the/DT
nonobese/JJ
population/NN
is/VBZ
not/RB
low/JJ
./.
====================
However/RB
,/,
the/DT
identification/NN
and/CC
risk/NN
mitigation/NN
of/IN
MS/NN
are/VBP
not/RB
easy/RB
in/IN
this/DT
population/NN
./.
====================
We/PRP
aimed/VBD
to/TO
develop/VB
an/DT
MS/NN
prediction/NN
model/NN
using/VBG
genetic/JJ
and/CC
clinical/JJ
factors/NNS
of/IN
nonobese/JJ
Koreans/NNS
through/IN
machine/NN
learning/VBG
methods/NNS
./.
====================
A/DT
prediction/NN
model/NN
for/IN
MS/NN
was/VBD
designed/VBN
for/IN
a/DT
nonobese/JJ
population/NN
using/VBG
clinical/JJ
and/CC
genetic/JJ
polymorphism/NN
information/NN
with/IN
five/CD
machine/JJ
learning/VBG
algorithms/NNS
,/,
including/VBG
naïve/JJ
Bayes/NNS
classification/NN
(/(
NB/NN
)/)
./.
====================
The/DT
analysis/NN
was/VBD
performed/VBN
in/IN
two/CD
stages/NNS
(/(
training/VBG
and/CC
test/NN
sets/NNS
)/)
./.
====================
Model/NNP
A/DT
was/VBD
designed/VBN
with/IN
only/RB
clinical/JJ
information/NN
(/(
age/NN
,/,
sex/NN
,/,
body/NN
mass/NN
index/NN
,/,
smoking/VBG
status/NN
,/,
alcohol/NN
consumption/NN
status/NN
,/,
and/CC
exercise/NN
status/NN
)/)
,/,
and/CC
for/IN
model/NN
B/NN
,/,
genetic/JJ
information/NN
(/(
for/IN
10/CD
polymorphisms/NNS
)/)
was/VBD
added/VBN
to/TO
model/VB
A/DT
./.
====================
Of/IN
the/DT
7,502/CD
nonobese/JJ
participants/NNS
,/,
647/CD
(/(
8.6/CD
%/NN
)/)
had/VBD
MS/NN
./.
====================
In/IN
the/DT
test/NN
set/NN
analysis/NN
,/,
for/IN
the/DT
maximum/NN
sensitivity/NN
criterion/NN
,/,
NB/NN
showed/VBD
the/DT
highest/JJS
sensitivity/NN
:/:
0.38/CD
for/IN
model/NN
A/DT
and/CC
0.42/CD
for/IN
model/NN
B/NN
./.
====================
The/DT
specificity/NN
of/IN
NB/NN
was/VBD
0.79/CD
for/IN
model/NN
A/NN
and/CC
0.80/CD
for/IN
model/NN
B/NN
./.
====================
In/IN
a/DT
comparison/NN
of/IN
the/DT
performances/NNS
of/IN
models/NNS
A/DT
and/CC
B/NN
by/IN
NB/NN
,/,
model/NN
B/NN
(/(
area/NN
under/IN
the/DT
receiver/NN
operating/VBG
characteristic/JJ
curve/JJ
[/(
AUC/NN
]/)
=/JJ
0.69/CD
,/,
clinical/JJ
and/CC
genetic/JJ
information/NN
input/IN
)/)
showed/VBD
better/IN
performance/NN
than/IN
model/NN
A/DT
(/(
AUC/NN
=/JJ
0.65/CD
,/,
clinical/JJ
information/NN
only/RB
input/RB
)/)
./.
====================
We/PRP
designed/VBD
a/DT
prediction/NN
model/NN
for/IN
MS/NN
in/IN
a/DT
nonobese/JJ
population/NN
using/VBG
clinical/JJ
and/CC
genetic/JJ
information/NN
./.
====================
With/IN
this/DT
model/NN
,/,
we/PRP
might/MD
convince/VB
nonobese/JJ
MS/NN
individuals/NNS
to/TO
undergo/VB
health/NN
checks/NNS
and/CC
adopt/JJ
behaviors/NNS
associated/VBN
with/IN
a/DT
preventive/JJ
lifestyle/JJ
./.
====================
Metabolic/JJ
syndrome/NN
refers/VBZ
to/TO
a/DT
state/NN
in/IN
which/WDT
multiple/JJ
diseases/NNS
,/,
such/JJ
as/IN
hyperglycemia/NN
,/,
hypertension/NN
,/,
hyperlipidemia/NN
,/,
and/CC
obesity/NN
,/,
occur/VBP
together/RB
in/IN
one/CD
individual/JJ
[/(
1/CD
]/)
./.
====================
Complications/NNS
of/IN
metabolic/JJ
syndrome/NN
may/MD
increase/VB
the/DT
incidence/NN
of/IN
cardiovascular/JJ
diseases/NNS
[/(
2/CD
]/)
,/,
and/CC
obstructive/JJ
sleep/JJ
apnea/NN
[/(
3/CD
]/)
or/CC
fatty/JJ
liver/NN
disease/NN
[/(
4/CD
]/)
may/MD
also/RB
occur/VBP
./.
====================
It/PRP
is/VBZ
known/VBN
that/IN
the/DT
occurrence/NN
or/CC
prognosis/NN
of/IN
colorectal/JJ
cancer/NN
[/(
5/CD
]/)
,/,
breast/NN
cancer/NN
[/(
6/CD
]/)
,/,
endometrial/JJ
cancer/NN
[/(
7/CD
,/,
8/CD
]/)
,/,
and/CC
prostate/NN
cancer/NN
[/(
9/CD
]/)
is/VBZ
closely/RB
related/JJ
to/TO
the/DT
constituents/NNS
of/IN
metabolic/JJ
syndrome/NN
[/(
10/CD
]/)
./.
====================
Therefore/RB
,/,
predicting/VBG
the/DT
group/NN
at/IN
high/JJ
risk/NN
for/IN
metabolic/JJ
syndrome/NN
and/CC
actively/RB
preventing/VBG
metabolic/JJ
syndrome/NN
are/VBP
essential/JJ
for/IN
health/NN
care/NN
./.
====================
The/DT
most/JJS
common/JJ
cause/VBP
of/IN
metabolic/JJ
syndrome/NN
has/VBZ
been/VBN
presumed/VBN
to/TO
be/VB
abdominal/JJ
obesity/NN
[/(
11/CD
]/)
./.
====================
In/IN
recent/JJ
years/NNS
,/,
however/RB
,/,
the/DT
need/NN
to/TO
consider/VB
nonobese/JJ
metabolic/JJ
syndrome/NN
has/VBZ
received/VBN
attention/NN
[/(
12/CD
]/)
./.
====================
Unlike/IN
obese/DT
metabolic/JJ
syndrome/NN
,/,
for/IN
which/WDT
body/NN
weight/NN
reductions/NNS
can/MD
decrease/VB
the/DT
risk/NN
and/CC
which/WDT
has/VBZ
received/VBN
much/RB
attention/NN
in/IN
health/NN
care/JJ
,/,
nonobese/JJ
metabolic/JJ
syndrome/NN
has/VBZ
no/DT
common/JJ
cause/VBP
,/,
such/JJ
as/IN
obesity/NN
./.
====================
Without/IN
a/DT
special/JJ
test/NN
,/,
it/PRP
is/VBZ
impossible/JJ
to/TO
detect/VB
or/CC
suspect/VB
metabolic/JJ
syndrome/NN
in/IN
nonobese/JJ
individuals/NNS
./.
====================
In/IN
the/DT
nonobese/JJ
metabolic/JJ
syndrome/NN
population/NN
,/,
the/DT
perception/NN
of/IN
health/NN
risks/NNS
is/VBZ
relatively/RB
low/JJ
and/CC
may/MD
be/VB
a/DT
blind/JJ
spot/NN
of/IN
health/NN
care/JJ
./.
====================
Genetic/JJ
studies/NNS
of/IN
metabolic/JJ
syndrome/NN
have/VBP
reported/VBN
a/DT
number/NN
of/IN
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
[/(
13–20/CD
]/)
that/IN
are/VBP
known/VBN
to/TO
be/VB
closely/RB
related/JJ
to/TO
clinical/JJ
factors/NNS
,/,
such/JJ
as/IN
aging/VBG
[/(
21/CD
]/)
,/,
sex/NN
[/(
22/CD
]/)
,/,
abdominal/JJ
obesity/NN
[/(
11/CD
]/)
,/,
physical/JJ
activity/NN
[/(
23/CD
]/)
,/,
alcohol/NN
consumption/NN
[/(
24/CD
]/)
,/,
and/CC
smoking/NN
[/(
25/CD
]/)
./.
====================
However/RB
,/,
no/DT
model/NN
has/VBZ
been/VBN
published/VBN
that/DT
combines/NNS
these/DT
clinical/JJ
and/CC
genetic/JJ
factors/NNS
in/IN
a/DT
metabolic/JJ
syndrome/NN
prediction/NN
model/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
constructed/VBD
a/DT
model/NN
to/TO
predict/VB
metabolic/JJ
syndrome/NN
in/IN
nonobese/JJ
people/JJ
using/VBG
machine/JJ
learning/VBG
algorithms/NNS
with/IN
factors/NNS
such/JJ
as/IN
age/NN
,/,
sex/NN
,/,
environmental/JJ
factors/NNS
,/,
and/CC
lifestyle/JJ
habits/VBZ
as/IN
well/RB
as/IN
genetic/JJ
predisposition/NN
factors/NNS
,/,
such/JJ
as/IN
SNPs/NNS
,/,
and/CC
evaluated/VBD
the/DT
performance/NN
of/IN
the/DT
model/NN
./.
====================
Study/NN
population/NN
====================
We/PRP
retrospectively/RB
used/VBN
the/DT
Gene-Environmental/JJ
Interaction/NN
and/CC
Phenotype/JJ
(/(
GENIE/NNP
)/)
database/NN
for/IN
Koreans/JJ
;/:
these/DT
data/NNS
were/VBD
collected/VBN
from/IN
10,349/CD
healthy/JJ
individuals/NNS
who/WP
visited/VBD
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
Gangnam/JJ
Center/JJ
for/IN
a/DT
comprehensive/JJ
health/NN
check-up/NN
and/CC
consented/VBD
to/TO
have/VB
their/PRP$
specimens/NNS
included/VBD
in/IN
a/DT
biospecimen/JJ
repository/JJ
./.
====================
The/DT
program/NN
for/IN
comprehensive/JJ
health/NN
check-ups/NNS
and/CC
the/DT
GENIE/NN
database/NN
is/VBZ
described/VBN
in/IN
another/DT
paper/NN
[/(
26/CD
]/)
./.
====================
Briefly/RB
,/,
blood/NN
pressure/NN
,/,
waist/NN
circumference/NN
,/,
height/RB
,/,
and/CC
weight/NN
information/NN
were/VBD
collected/VBN
through/IN
anthropometric/JJ
measurements/NNS
during/IN
a/DT
health/NN
screening/NN
,/,
and/CC
information/NN
on/IN
age/NN
,/,
smoking/VBG
,/,
alcohol/NN
,/,
exercise/RB
,/,
and/CC
drug/NN
use/NN
was/VBD
collected/VBN
through/IN
interviews/VBZ
./.
====================
After/IN
at/IN
least/JJS
10/CD
hours/NNS
of/IN
fasting/JJ
,/,
peripheral/JJ
blood/NN
samples/NNS
were/VBD
obtained/VBN
from/IN
all/DT
patients/NNS
to/TO
determine/VB
the/DT
levels/NNS
of/IN
fasting/JJ
glucose/NN
,/,
triglycerides/VBZ
,/,
high-density/JJ
lipopolysaccharide/NN
(/(
HDL/NN
)/)
cholesterol/NN
,/,
and/CC
DNA/NN
samples/NNS
were/VBD
collected/VBN
from/IN
the/DT
remaining/VBG
blood/NN
./.
====================
SNP/NN
genotyping/VBG
was/VBD
performed/VBN
by/IN
an/DT
Affymetrix/JJ
Axiom/NNP
KORV1.1-96/CD
Array/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
at/IN
DNA/NN
Link/NN
Inc./NNP
(/(
Seoul/JJ
,/,
Korea/NN
)/)
./.
====================
Ethics/NNS
statement/JJ
====================
The/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
the/DT
Seoul/JJ
National/JJ
University/NN
Hospital/JJ
approved/JJ
this/DT
study/NN
protocol/NN
(/(
IRB/NN
number/NN
H-1807-030-955/NN
)/)
,/,
and/CC
informed/VBN
consent/NN
was/VBD
waived/VBN
by/IN
the/DT
board/JJ
./.
====================
The/DT
study/NN
was/VBD
conducted/VBN
in/IN
accordance/NN
with/IN
the/DT
Declaration/NN
of/IN
Helsinki/NN
./.
====================
Clinical/JJ
assessment/NN
and/CC
definitions/NNS
====================
For/IN
this/DT
study/RB
,/,
metabolic/JJ
syndrome/DT
is/VBZ
defined/VBN
according/VBG
to/TO
the/DT
International/JJ
Diabetes/NNS
Federation/NN
’/RB
s/NNS
criteria/NNS
for/IN
the/DT
South/NN
Asian/JJ
ethnic/JJ
group/NN
[/(
27/CD
]/)
,/,
that/IN
is/VBZ
,/,
the/DT
presence/NN
of/IN
at/IN
least/JJS
3/LS
of/IN
the/DT
following/VBG
metabolic/JJ
risk/NN
factors/NNS
:/:
increased/VBD
waist/RB
circumference/RB
(/(
males/NNS
≥/RB
90/CD
cm/RB
;/:
females/NNS
≥/RB
80/CD
cm/RB
)/)
;/:
elevated/JJ
blood/NN
pressure/RB
(/(
≥130/85/CD
mm/NN
Hg/NNP
or/CC
the/DT
use/NN
of/IN
medications/NNS
for/IN
hypertension/NN
)/)
;/:
elevated/JJ
fasting/JJ
glucose/DT
levels/NNS
(/(
fasting/VBG
glucose/DT
≥/NNP
100/CD
mg/dL/NN
or/CC
the/DT
use/NN
of/IN
medications/NNS
for/IN
hyperglycemia/NN
)/)
;/:
elevated/JJ
triglyceride/NN
levels/NNS
(/(
≥150/CD
mg/dL/NN
)/)
;/:
and/CC
reduced/VBD
HDL/NN
cholesterol/NN
levels/NNS
(/(
males/NNS
</JJR
40/CD
mg/dL/NN
,/,
females/NNS
</JJR
50/CD
mg/dL/NN
)/)
or/CC
being/VBG
under/IN
treatment/JJ
for/IN
dyslipidemia/NN
./.
====================
The/DT
metabolic/JJ
score/NN
is/VBZ
the/DT
sum/NN
of/IN
the/DT
number/NN
of/IN
metabolic/JJ
risk/NN
factors/NNS
./.
====================
Alcohol/NN
consumption/NN
was/VBD
defined/VBN
as/IN
yes/NNS
when/WRB
more/RBR
than/IN
140/CD
g/NN
of/IN
alcohol/NN
was/VBD
consumed/VBN
per/IN
week/NN
,/,
and/CC
smoking/NN
status/NN
was/VBD
categorized/VBN
as/IN
no/DT
or/CC
ex-smokers/NNS
vs./CC
current/JJ
smoker/NN
./.
====================
Exercise/RB
was/VBD
grouped/VBN
as/IN
not/RB
active/JJ
vs./CC
physically/RB
active/JJ
./.
====================
Physically/RB
active/JJ
was/VBD
defined/VBN
as/IN
performing/JJ
at/IN
least/JJS
150/CD
minutes/NNS
of/IN
vigorous/JJ
or/CC
moderate/JJ
intensity/NN
active/JJ
per/IN
week/NN
./.
====================
The/DT
study/NN
was/VBD
conducted/VBN
in/IN
nonobese/JJ
individuals/NNS
whose/WP$
body/NN
mass/NN
index/NN
(/(
BMI/NN
)/)
was/VBD
less/RBR
than/IN
25/CD
kg/m2/NN
./.
====================
Genotyping/VBG
and/CC
quality/NN
control/NN
====================
Genomic/JJ
DNA/NN
was/VBD
separated/VBN
from/IN
venous/JJ
blood/NN
samples/NNS
,/,
and/CC
200/CD
ng/NN
was/VBD
genotyped/VBN
using/VBG
a/DT
Hybridization/NN
on/IN
Affymetrix/JJ
Axiom/NNP
KORV1.0-96/CD
Array/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
)/)
./.
====================
The/DT
PLINK/NN
program/NN
version/NN
1.9/CD
(/(
https/NNS
:/:
//www.cog-genomics.org/plink2/NN
)/)
was/VBD
used/VBN
for/IN
the/DT
quality/NN
control/NN
process/NN
for/IN
the/DT
raw/NN
genotype/NN
data/NNS
,/,
resulting/VBG
in/IN
a/DT
total/JJ
of/IN
586,730/CD
SNPs/NNS
to/TO
be/VB
used/VBN
./.
====================
SNPs/NNS
with/IN
case/NN
and/CC
control/NN
minor/JJ
allele/NN
frequencies/NNS
less/RBR
than/IN
1/CD
%/NN
,/,
case/NN
or/CC
control/JJ
call/JJ
rates/NNS
less/RBR
than/IN
95/CD
%/NN
or/CC
a/DT
significant/JJ
deviation/NN
from/IN
Hardy–Weinberg/JJ
equilibrium/NN
in/IN
the/DT
controls/NNS
(/(
p/NN
</JJR
0.0001/CD
)/)
were/VBD
excluded/VBN
./.
====================
SNP/NN
selection/NN
for/IN
analysis/NN
====================
To/TO
design/VB
a/DT
model/NN
for/IN
predicting/VBG
metabolic/JJ
syndrome/NN
in/IN
the/DT
nonobese/JJ
population/NN
,/,
we/PRP
selected/VBD
the/DT
SNPs/NNS
in/IN
two/CD
ways/NNS
./.
====================
In/IN
the/DT
first/JJ
way/NN
,/,
we/PRP
used/VBD
the/DT
genome-wide/NN
association/NN
study/NN
(/(
GWAS/NN
)/)
catalog/NN
database/NN
./.
====================
We/PRP
extracted/VBD
the/DT
SNP/NN
list/NN
from/IN
the/DT
GWAS/JJ
Catalog/NN
with/IN
keywords/JJ
such/JJ
as/IN
“/RB
metabolic/JJ
syndrome/NN
,/,
”/NNP
“/NNP
obesity/NN
,/,
”/NNP
and/CC
“/FW
adipose/DT
tissue./FW
”/NNP
For/IN
the/DT
extracted/JJ
SNPs/NNS
,/,
we/PRP
used/VBD
SNPs/NNS
that/IN
were/VBD
included/VBN
among/IN
the/DT
SNPs/NNS
of/IN
the/DT
Affymetrix/JJ
Axiom/NNP
KORV1.0-96/CD
Array/NN
(/(
Affymetrix/JJ
,/,
Santa/NNP
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
and/CC
had/VBD
a/DT
p-value/JJ
of/IN
less/RBR
than/IN
0.01/CD
in/IN
the/DT
case/NN
control/JJ
study/NN
for/IN
metabolic/JJ
syndrome/NN
in/IN
our/PRP$
nonobese/JJ
population/NN
./.
====================
In/IN
the/DT
second/JJ
way/NN
,/,
we/PRP
performed/VBD
a/DT
GWAS/JJ
study/NN
for/IN
metabolic/JJ
syndrome/NN
in/IN
our/PRP$
nonobese/JJ
population/NN
and/CC
selected/VBN
the/DT
SNPs/NNS
with/IN
p-values/NNS
that/DT
passed/VBN
the/DT
Bonferroni-corrected/JJ
threshold/JJ
(/(
p/NN
</JJR
8.52/CD
×/CD
10−8/CD
)/)
./.
====================
We/PRP
included/VBD
all/DT
the/DT
SNPs/NNS
selected/VBN
using/VBG
both/CC
ways/NNS
to/TO
design/VB
the/DT
algorithm/NN
./.
====================
Prediction/NN
model/NN
design/NN
by/IN
machine/NN
learning/VBG
tools/NNS
====================
For/IN
the/DT
nonobese/JJ
population/NN
(/(
BMI/NNP
</JJR
25/CD
kg/m2/RB
)/)
population/NN
,/,
the/DT
clinical/JJ
information/NN
(/(
age/RB
,/,
sex/RB
,/,
BMI/NNP
,/,
smoking/VBG
history/JJ
,/,
alcohol/RB
consumption/NN
history/JJ
,/,
and/CC
exercise/RB
)/)
and/CC
SNPs/NNS
selected/VBN
as/IN
described/VBN
above/IN
(/(
finally/RB
,/,
10/CD
SNPs/NNS
were/VBD
selected/VBN
:/:
rs3764261/RB
,/,
rs247617/RB
,/,
rs2266788/RB
,/,
rs964184/RB
,/,
rs10830963/RB
,/,
rs1260326/RB
,/,
rs10830962/RB
,/,
rs1883025/RB
,/,
rs1919128/RB
,/,
and/CC
rs11757661/RB
)/)
were/VBD
used/VBN
to/TO
perform/CC
five/CD
types/NNS
of/IN
machine/JJ
learning/VBG
analysis/NN
,/,
multilayer/JJ
perceptron/RB
(/(
MLP/NN
)/)
[/(
28/CD
]/)
,/,
naïve/RB
Bayes/NNS
classification/NN
(/(
NB/NN
)/)
[/(
29/CD
]/)
,/,
random/RB
forest/IN
classification/NN
(/(
RF/NN
)/)
[/(
30/CD
]/)
,/,
decision/RB
trees/NNS
classification/NN
(/(
J48/NNP
)/)
[/(
31/CD
]/)
,/,
and/CC
support/VBP
vector/RB
machine/JJ
classification/NN
(/(
SVM/NNP
)/)
[/(
32/CD
]/)
,/,
to/TO
predict/VB
metabolic/JJ
syndrome/DT
./.
====================
The/DT
additive/JJ
model/NN
was/VBD
used/VBN
for/IN
genotype/NN
data/NNS
used/VBN
./.
====================
The/DT
total/JJ
population/NN
was/VBD
divided/VBN
into/IN
sets/NNS
in/IN
a/DT
7:3/CD
ratio/NN
for/IN
the/DT
training/VBG
set/NN
,/,
which/WDT
was/VBD
used/VBN
to/TO
develop/VB
the/DT
model/NN
,/,
relative/JJ
to/TO
the/DT
test/NN
set/NN
,/,
which/WDT
was/VBD
used/VBN
to/TO
validate/VB
the/DT
resulting/VBG
model/NN
./.
====================
The/DT
performance/NN
of/IN
the/DT
model/NN
was/VBD
evaluated/VBN
according/VBG
to/TO
accuracy/VB
,/,
specificity/NN
,/,
sensitivity/NN
,/,
F1/NN
score/RB
,/,
and/CC
the/DT
balanced/JJ
classification/NN
rate/NN
./.
====================
Model/NN
A/NN
was/VBD
designed/VBN
with/IN
only/RB
clinical/JJ
information/NN
,/,
and/CC
model/NN
B/NN
also/RB
included/VBD
genetic/JJ
information/NN
(/(
information/NN
about/IN
the/DT
10/CD
SNPs/NNS
)/)
./.
====================
The/DT
machine/NN
learning/VBG
analysis/NN
was/VBD
conducted/VBN
by/IN
Weka/NN
(/(
Waikato/NN
Environment/JJ
for/IN
Knowledge/NN
Analysis/NN
;/:
University/NN
of/IN
Waikato/NN
,/,
Hamilton/JJ
,/,
New/NN
Zealand/NN
)/)
./.
====================
All/DT
analyses/NNS
were/VBD
two-tailed/VBN
,/,
and/CC
p-values/NNS
</JJR
0.05/CD
were/VBD
considered/VBN
statistically/RB
significant/JJ
./.
====================
Statistical/JJ
tests/NNS
were/VBD
performed/VBN
using/VBG
PLINK/NN
version/NN
1.9/CD
(/(
https/NNS
:/:
//www.cog-genomics.org/plink2/NN
)/)
,/,
R/NN
statistical/JJ
software/NN
(/(
version/NN
3.4.4/CD
)/)
was/VBD
used/VBN
for/IN
statistical/JJ
analyses/NNS
,/,
and/CC
p-values/NNS
less/RBR
than/IN
0.05/CD
were/VBD
considered/VBN
significant/JJ
./.
====================
The/DT
study/NN
outline/NN
is/VBZ
demonstrated/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
Statistical/JJ
analysis/NN
====================
For/IN
the/DT
GWAS/NN
,/,
logistic/JJ
regression/NN
analyses/NNS
were/VBD
used/VBN
,/,
controlling/VBG
for/IN
sex/NN
as/IN
a/DT
covariate/JJ
in/IN
the/DT
additive/JJ
model/NN
./.
====================
The/DT
performance/NN
was/VBD
compared/VBN
between/IN
model/NN
A/DT
(/(
clinical/JJ
data/NNS
input/VBP
only/RB
)/)
and/CC
model/NN
B/NN
(/(
clinical/JJ
data/NNS
+/CC
genetic/JJ
data/NNS
input/VBP
)/)
by/IN
drawing/VBG
the/DT
receiver/NN
operating/VBG
characteristic/JJ
(/(
ROC/NN
)/)
curve/VBP
and/CC
comparing/VBG
the/DT
area/NN
under/IN
the/DT
curve/JJ
confusion/NN
matrix/NN
./.
====================
Statistical/JJ
tests/NNS
were/VBD
performed/VBN
using/VBG
PLINK/NN
version/NN
1.9/CD
(/(
https/NNS
:/:
//www.cog-genomics.org/plink2/NN
)/)
,/,
SAS/NN
9.1/CD
(/(
SAS/NN
Institute/JJ
Inc./NNP
,/,
Cary/NN
,/,
NC/NN
,/,
USA/NNP
)/)
and/CC
R/NN
3.2.2/CD
(/(
R/NN
Development/NN
Core/NN
Team/JJ
;/:
R/NN
Foundation/NN
for/IN
Statistical/JJ
Computing/JJ
,/,
Vienna/NNP
,/,
Austria/NNP
)/)
./.
====================
Study/NN
population/NN
characteristics/NNS
====================
The/DT
10,349/CD
participants/NNS
included/VBD
7,502/CD
nonobese/JJ
individuals/NNS
./.
====================
Metabolic/JJ
syndrome/NN
was/VBD
observed/VBN
in/IN
647/CD
(/(
8.6/CD
%/NN
)/)
persons/NNS
./.
====================
The/DT
nonobese/JJ
individuals/NNS
were/VBD
grouped/VBN
into/IN
a/DT
training/JJ
set/NN
(/(
n/NN
=/JJ
5,251/CD
)/)
and/CC
a/DT
test/NN
set/NN
(/(
n/NN
=/JJ
2,251/CD
)/)
,/,
and/CC
the/DT
baseline/NN
characteristics/NNS
are/VBP
shown/VBN
in/IN
Table/JJ
1/CD
./.
====================
Age/RB
,/,
sex/NN
,/,
BMI/NN
,/,
smoking/NN
status/NN
,/,
alcohol/NN
consumption/NN
status/NN
,/,
and/CC
exercise/NN
status/NN
information/NN
were/VBD
input/RB
into/IN
model/NN
A/DT
,/,
and/CC
SNP/NN
information/NN
was/VBD
additionally/RB
input/NN
into/IN
model/NN
B/NN
./.
====================
The/DT
SNP/NN
information/NN
is/VBZ
described/VBN
in/IN
Table/JJ
2/CD
./.
====================
Overall/RB
comparison/NN
of/IN
the/DT
various/JJ
machine/NN
learning/VBG
tools/NNS
====================
We/PRP
used/VBD
six/CD
machine/NN
learning/VBG
methods/NNS
,/,
namely/RB
,/,
MLP/NN
,/,
NB/NN
,/,
RF/NN
,/,
decision/NN
tree/CD
classification/NN
,/,
and/CC
SVM/NN
./.
====================
Table/JJ
3/CD
summarizes/VBZ
the/DT
performance/NN
of/IN
each/DT
model/NN
obtained/VBN
with/IN
the/DT
various/JJ
machine/NN
learning/VBG
tools/NNS
in/IN
the/DT
training/VBG
and/CC
test/NN
sets/NNS
./.
====================
The/DT
purpose/NN
of/IN
generating/VBG
our/PRP$
models/NNS
is/VBZ
to/TO
provide/VB
a/DT
warning/VBG
for/IN
a/DT
nonobese/JJ
person/NN
who/WP
has/VBZ
an/DT
increased/VBN
risk/NN
for/IN
metabolic/JJ
syndrome/NN
./.
====================
Therefore/RB
,/,
we/PRP
evaluated/VBD
the/DT
sensitivity/NN
of/IN
the/DT
designed/VBN
model/NN
./.
====================
NB/NN
showed/VBD
the/DT
best/JJS
sensitivity/NN
,/,
0.38/CD
for/IN
model/NN
A/NN
and/CC
0.42/CD
for/IN
model/NN
B/NN
./.
====================
The/DT
specificity/NN
of/IN
NB/NN
was/VBD
0.79/CD
for/IN
model/NN
A/NN
and/CC
0.80/CD
for/IN
model/NN
B/NN
./.
====================
Performance/NN
comparison/NN
between/IN
model/NN
A/NN
and/CC
model/NN
B/NN
====================
Via/NN
the/DT
area/NN
under/IN
the/DT
ROC/NN
curve/NN
(/(
AUC/NN
)/)
,/,
we/PRP
compared/VBD
the/DT
performance/NN
of/IN
model/NN
A/DT
and/CC
model/NN
B/NN
obtained/VBN
with/IN
NB/NN
./.
====================
Model/NNP
B/NN
(/(
AUC/NN
=/JJ
0.69/CD
)/)
,/,
for/IN
which/WDT
the/DT
input/NN
factors/NNS
were/VBD
the/DT
SNP/NN
information/NN
in/IN
addition/NN
to/TO
the/DT
factors/NNS
used/VBN
in/IN
model/NN
A/DT
,/,
showed/VBD
better/IN
performance/NN
than/IN
model/NN
A/DT
(/(
AUC/NN
=/JJ
0.65/CD
)/)
,/,
for/IN
which/WDT
the/DT
input/NN
factors/NNS
were/VBD
age/NN
,/,
sex/NN
,/,
BMI/NNP
,/,
smoking/VBG
status/NN
,/,
alcohol/NN
consumption/NN
status/NN
,/,
and/CC
exercise/RB
status/NN
./.
====================
This/DT
study/NN
designed/VBD
a/DT
predictive/JJ
model/NN
for/IN
metabolic/JJ
syndrome/NN
in/IN
nonobese/JJ
people/NN
through/IN
machine/NN
learning/VBG
using/VBG
clinical/JJ
information/NN
and/CC
polymorphism/NN
information/NN
obtained/VBN
at/IN
a/DT
health/NN
screening/NN
./.
====================
Among/IN
the/DT
various/JJ
machine/NN
learning/VBG
methods/NNS
,/,
NB/NN
showed/VBD
the/DT
best/JJS
performance/RB
,/,
and/CC
the/DT
prediction/NN
model/NN
that/DT
included/VBD
genetic/JJ
information/NN
showed/VBD
better/RBR
performance/NN
than/IN
the/DT
prediction/NN
model/NN
designed/VBN
with/IN
only/RB
clinical/JJ
data/NNS
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
people/JJ
with/IN
metabolic/JJ
syndrome/NN
have/VBP
a/DT
5-fold/JJ
increased/VBD
risk/NN
of/IN
developing/VBG
type/NN
2/CD
diabetes/NNS
mellitus/NN
,/,
a/DT
3-fold/JJ
increased/VBD
risk/NN
of/IN
developing/VBG
cardiovascular/JJ
disease/NN
[/(
1/CD
]/)
,/,
and/CC
increased/VBD
cancer/NN
risk/NN
and/CC
cancer-related/VBD
mortality/NN
[/(
5–9/CD
]/)
./.
====================
Therefore/RB
,/,
predicting/VBG
the/DT
population/NN
with/IN
a/DT
high/JJ
risk/NN
for/IN
metabolic/JJ
syndrome/NN
and/CC
actively/RB
intervening/VBG
with/IN
these/DT
individuals/NNS
are/VBP
very/RB
important/JJ
for/IN
promoting/VBG
health/NN
./.
====================
Obesity/NN
is/VBZ
the/DT
most/JJS
common/JJ
risk/NN
factor/NN
for/IN
metabolic/JJ
syndrome/NN
./.
====================
Obesity/NN
is/VBZ
known/VBN
to/TO
be/VB
associated/VBN
with/IN
complications/NNS
such/JJ
as/IN
diabetes/NNS
,/,
hypertension/NN
,/,
and/CC
cardiovascular/JJ
disease/NN
[/(
33/CD
,/,
34/CD
]/)
./.
====================
Obesity/NN
is/VBZ
clinically/RB
evident/JJ
,/,
so/RB
obese/DT
people/NN
can/MD
recognize/VB
the/DT
risk/NN
and/CC
prevent/VBP
metabolic/JJ
syndrome/NN
from/IN
occurring/VBG
by/IN
undergoing/VBG
aggressive/JJ
weight/NN
loss/NN
efforts/NNS
./.
====================
However/RB
,/,
metabolic/JJ
disturbance/NN
can/MD
also/RB
occur/VBP
in/IN
nonobese/JJ
people/NN
./.
====================
One/CD
cohort/NN
study/NN
reported/VBD
that/IN
reduced/VBD
inflammatory/JJ
status/NN
,/,
which/WDT
is/VBZ
a/DT
metabolic/JJ
syndrome/NN
pathogenesis/NN
,/,
is/VBZ
observed/VBN
in/IN
nonobese/JJ
patients/NNS
as/IN
well/RB
as/IN
obese/DT
patients/NNS
[/(
35/CD
,/,
36/CD
]/)
./.
====================
The/DT
problem/NN
for/IN
these/DT
nonobese/JJ
patients/NNS
is/VBZ
that/DT
without/IN
a/DT
specific/JJ
biochemical/JJ
test/NN
,/,
these/DT
individuals/NNS
do/VBP
not/RB
know/VB
if/IN
they/PRP
have/VBP
developed/VBN
metabolic/JJ
syndrome/NN
and/CC
that/IN
they/PRP
do/VBP
not/RB
know/VB
if/IN
they/PRP
are/VBP
at/IN
risk/NN
for/IN
metabolic/JJ
syndrome/NN
./.
====================
The/DT
prevalence/NN
of/IN
undiagnosed/JJ
metabolic/JJ
syndrome/NN
in/IN
people/JJ
with/IN
normal/JJ
BMI/NN
is/VBZ
reported/VBN
to/TO
be/VB
5.2/CD
%/NN
–8.9/CD
%/NN
[/(
37/CD
]/)
./.
====================
Therefore/RB
,/,
predicting/VBG
these/DT
factors/NNS
plays/VBZ
a/DT
very/RB
important/JJ
role/NN
in/IN
health/NN
care/NN
./.
====================
To/TO
increase/VB
the/DT
predictive/JJ
power/JJR
in/IN
this/DT
group/NN
,/,
we/PRP
made/VBD
a/DT
prediction/NN
model/NN
including/VBG
genetic/JJ
factors/NNS
as/IN
well/RB
as/IN
clinical/JJ
factors/NNS
and/CC
performed/VBN
analysis/NN
through/IN
various/JJ
kinds/NNS
of/IN
machine/NN
learning/VBG
./.
====================
Naïve/JJ
Bayes/NNS
classification/NN
showed/VBD
the/DT
best/JJS
performance/NN
./.
====================
The/DT
naïve/JJ
Bayesian/JJ
classifier/NN
(/(
NBC/NN
)/)
is/VBZ
a/DT
powerful/JJ
probabilistic/JJ
model/NN
that/DT
has/VBZ
been/VBN
applied/VBN
in/IN
various/JJ
medical/JJ
studies/NNS
[/(
38/CD
,/,
39/CD
]/)
./.
====================
The/DT
superiority/NN
of/IN
the/DT
NBC/NN
is/VBZ
that/DT
it/PRP
takes/VBZ
all/DT
information/NN
into/IN
account/VBP
to/TO
reach/VB
a/DT
decision/NN
,/,
which/WDT
is/VBZ
natural/JJ
way/NN
for/IN
physicians/NNS
to/TO
make/VB
diagnostic/JJ
and/CC
prognostic/JJ
decisions/NNS
[/(
40/CD
]/)
./.
====================
This/DT
study/NN
has/VBZ
the/DT
following/VBG
limitations/NNS
./.
====================
First/RB
,/,
only/RB
Korean/JJ
individuals/NNS
were/VBD
included/VBN
./.
====================
Therefore/RB
,/,
for/IN
generalization/NN
to/TO
other/JJ
ethnicities/NNS
,/,
it/PRP
is/VBZ
necessary/JJ
to/TO
expand/VB
the/DT
study/NN
to/TO
include/VB
other/JJ
ethnicities/NNS
as/IN
well/RB
./.
====================
Second/RB
,/,
although/IN
the/DT
naïve/JJ
Bayesian/JJ
algorithm/NN
has/VBZ
the/DT
best/JJS
performance/NN
,/,
its/PRP$
sensitivity/NN
of/IN
0.42/CD
is/VBZ
not/RB
sufficient/JJ
./.
====================
In/IN
future/JJ
studies/NNS
,/,
it/PRP
is/VBZ
necessary/JJ
to/TO
improve/VB
performance/NN
by/IN
applying/VBG
a/DT
deep/JJ
learning/VBG
algorithm/NN
./.
====================
The/DT
superiority/NN
of/IN
this/DT
study/NN
is/VBZ
as/IN
follows/VBZ
./.
====================
First/RB
,/,
we/PRP
constructed/VBD
a/DT
prediction/NN
model/NN
by/IN
integrating/VBG
clinical/JJ
information/NN
,/,
environmental/JJ
factors/NNS
,/,
and/CC
genetic/JJ
information/NN
./.
====================
Genetic/JJ
studies/NNS
of/IN
metabolic/JJ
syndrome/NN
have/VBP
been/VBN
reported/VBN
mostly/RB
for/IN
SNPs/NNS
and/CC
are/VBP
clinically/RB
known/VBN
to/TO
be/VB
caused/VBN
by/IN
several/JJ
environmental/JJ
factors/NNS
./.
====================
However/RB
,/,
no/DT
method/NN
or/CC
algorithms/NNS
have/VBP
been/VBN
published/VBN
for/IN
integrating/VBG
big/NN
data/NNS
information/NN
,/,
which/WDT
is/VBZ
the/DT
result/NN
of/IN
these/DT
individual/JJ
studies/NNS
,/,
into/IN
a/DT
metabolic/JJ
syndrome/NN
prediction/NN
model/NN
for/IN
nonobese/JJ
populations/NNS
./.
====================
In/IN
metabolic/JJ
syndrome/NN
,/,
not/RB
only/RB
the/DT
genetic/JJ
polymorphism/NN
of/IN
SNPs/NNS
but/CC
also/RB
factors/NNS
such/JJ
as/IN
age/NN
,/,
sex/NN
,/,
environmental/JJ
factors/NNS
,/,
and/CC
lifestyle/JJ
habits/VBZ
are/VBP
all/DT
involved/VBN
,/,
and/CC
the/DT
presence/NN
of/IN
these/DT
genetic/JJ
and/CC
clinical/JJ
factors/NNS
controls/VBZ
the/DT
development/NN
of/IN
metabolic/JJ
syndrome/NN
./.
====================
In/IN
addition/NN
,/,
although/IN
the/DT
GWASs/NNS
used/VBN
in/IN
the/DT
existing/VBG
SNP/NN
analysis/NN
found/VBD
SNPs/NNS
that/DT
are/VBP
candidate/NN
markers/NNS
for/IN
a/DT
number/NN
of/IN
metabolic/JJ
disorders/NNS
,/,
all/DT
of/IN
the/DT
studies/NNS
considered/VBN
individual/JJ
SNPs/NNS
,/,
and/CC
no/DT
studies/NNS
have/VBP
analyzed/VBN
SNPs/NNS
in/IN
an/DT
integrated/JJ
manner/NN
./.
====================
Second/JJ
,/,
machine/NN
learning/VBG
was/VBD
used/VBN
to/TO
build/JJ
predictive/JJ
models/NNS
./.
====================
The/DT
traditional/JJ
construction/NN
of/IN
models/NNS
by/IN
statistical/JJ
methods/NNS
is/VBZ
mostly/RB
conducted/VBN
with/IN
only/RB
clinical/JJ
information/NN
,/,
and/CC
factors/NNS
in/IN
the/DT
prediction/NN
model/NN
that/DT
have/VBP
borderline/VBN
influence/VBP
are/VBP
often/RB
deleted/VBN
during/IN
the/DT
model/NN
design/NN
process/NN
./.
====================
Additionally/RB
,/,
for/IN
the/DT
traditional/JJ
models/NNS
,/,
it/PRP
is/VBZ
difficult/JJ
to/TO
reflect/VB
all/DT
the/DT
associations/NNS
between/IN
the/DT
factors/NNS
./.
====================
In/IN
the/DT
case/NN
of/IN
machine/NN
learning/VBG
,/,
data/NNS
and/CC
factors/NNS
of/IN
borderline/JJ
significance/NN
can/MD
be/VB
considered/VBN
in/IN
the/DT
analysis/NN
without/IN
overlooking/VBG
data/NNS
that/WDT
are/VBP
not/RB
well/RB
known/VBN
./.
====================
Third/RB
,/,
model/NN
A/DT
in/IN
our/PRP$
study/NN
,/,
which/WDT
is/VBZ
designed/VBN
only/RB
using/VBG
clinical/JJ
information/NN
,/,
itself/PRP
has/VBZ
useful/JJ
value/NN
in/IN
the/DT
clinical/JJ
field/NN
./.
====================
Model/NN
A/NN
used/VBN
information/NN
such/JJ
as/IN
age/NN
,/,
sex/NN
,/,
body/NN
mass/NN
index/NN
,/,
smoking/NN
,/,
alcohol/NN
consumption/NN
,/,
and/CC
exercise/NN
./.
====================
This/DT
information/NN
can/MD
be/VB
obtained/VBN
easily/RB
without/IN
any/DT
special/JJ
medical/JJ
inspection/NN
./.
====================
If/IN
a/DT
nonobese/JJ
person/NN
inputs/VBZ
their/PRP$
information/NN
into/IN
the/DT
algorithms/NNS
,/,
they/PRP
can/MD
be/VB
alerted/VBN
to/TO
their/PRP$
risk/NN
of/IN
metabolic/JJ
syndrome/NN
and/CC
take/VBP
active/JJ
interventions/NNS
to/TO
prevent/VB
complications/NNS
./.
====================
This/DT
application/NN
can/MD
be/VB
performed/VBN
by/IN
the/DT
nonobsese/JJ
person/NN
himself/NN
or/CC
herself/PRP
without/IN
the/DT
help/NN
of/IN
a/DT
medical/JJ
specialist/NN
./.
====================
After/IN
conducting/VBG
a/DT
replication/NN
study/NN
in/IN
another/DT
population/NN
set/NN
and/CC
improving/VBG
the/DT
performance/NN
of/IN
this/DT
model/NN
,/,
we/PRP
are/VBP
planning/VBG
to/TO
make/VB
it/PRP
accessible/JJ
as/IN
a/DT
website/JJ
in/IN
the/DT
future/JJ
./.
====================
In/IN
this/DT
study/NN
,/,
a/DT
prediction/NN
model/NN
was/VBD
constructed/VBN
by/IN
integrating/VBG
clinical/JJ
information/NN
,/,
environmental/JJ
factors/NNS
,/,
and/CC
genetic/JJ
information/NN
./.
====================
The/DT
purpose/NN
of/IN
this/DT
study/NN
is/VBZ
to/TO
provide/VB
a/DT
prediction/NN
model/NN
for/IN
metabolic/JJ
syndrome/NN
that/DT
is/VBZ
more/RBR
predictive/JJ
of/IN
metabolic/JJ
syndrome/NN
than/IN
previous/JJ
models/NNS
,/,
by/IN
using/VBG
clinical/JJ
and/CC
genetic/JJ
markers/NNS
related/JJ
to/TO
metabolic/JJ
syndrome/NN
specifically/RB
in/IN
a/DT
nonobese/JJ
population/NN
./.
====================
Using/VBG
this/DT
prediction/NN
model/NN
,/,
we/PRP
could/MD
predict/VB
the/DT
group/NN
of/IN
nonobese/JJ
individuals/NNS
who/WP
have/VBP
a/DT
high/JJ
risk/NN
of/IN
developing/VBG
metabolic/JJ
syndrome/NN
./.
====================
For/IN
the/DT
individuals/NNS
in/IN
this/DT
group/NN
who/WP
previously/RB
did/VBD
not/RB
feel/NN
a/DT
need/JJ
to/TO
use/VB
healthcare/JJ
services/VBZ
and/CC
were/VBD
not/RB
concerned/VBN
about/RB
metabolic/JJ
syndrome/NN
,/,
we/PRP
could/MD
encourage/VB
them/PRP
to/TO
receive/JJ
health/NN
checks/NNS
and/CC
modify/VB
their/PRP$
lifestyle/JJ
to/TO
include/VB
preventive/JJ
habits/VBZ
./.
====================
This/DT
process/NN
would/MD
save/VB
them/PRP
from/IN
cardiovascular/JJ
disease/NN
and/CC
several/JJ
cancers/NNS
that/DT
are/VBP
complications/NNS
of/IN
metabolic/JJ
syndrome/NN
./.
====================
This/DT
can/MD
be/VB
used/VBN
as/IN
part/NN
of/IN
a/DT
more/RBR
comprehensive/JJ
health/NN
care/NN
method/NN
./.
====================
Study/NN
flow/NN
pipeline/NN
./.
====================
SNP/NN
,/,
single/JJ
nucleotide/NN
polymorphism/NN
;/:
MLP/NN
,/,
multilayer/JJ
perceptron/NN
;/:
NB/NN
,/,
naïve/JJ
Bayes/NNS
classification/NN
;/:
RF/NN
,/,
random/JJ
forest/JJS
classification/NN
;/:
CT/NN
,/,
decision/NN
tree/CD
classification/NN
;/:
SVM/NN
,/,
support/VBP
vector/NN
machine/NN
classification/NN
;/:
BCR/NN
,/,
balanced/JJ
classification/NN
rate/NN
./.
====================
Demographic/JJ
features/NNS
of/IN
the/DT
training/VBG
and/CC
test/NN
set/NN
populations/NNS
====================
Information/NN
on/IN
the/DT
SNPs/NNS
used/VBN
in/IN
the/DT
algorithm/NN
====================
Performance/NN
comparison/NN
among/IN
respective/JJ
machine/NN
learning/VBG
algorithms/NNS
for/IN
predicting/VBG
metabolic/JJ
syndrome/NN
presence/NN
====================
